Abdul M A, Ibrahim U N, Yusuf M D, Musa H
Department of Obstetrics and Gynaecology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
West Afr J Med. 2007 Jul-Sep;26(3):213-6. doi: 10.4314/wajm.v26i3.28312.
Misoprostol - a stable prostaglandin E1 analogue- is effective and safe in the induction of labour. There is paucity of information about the use of misoprostol for labour induction in Nigeria.
To evaluate the efficacy of misoprostol in the induction of labour in the third trimester. METHODS. Consecutive patients for induction of labour were randomized into misoprostol or oxytocin study groups. The misoprostol group received intravaginal 50 microg 6- hourly to a maximum of four doses. Those in the oxytocin group received a maximum of 48 iu/min. Outcome measures included induction-delivery interval, mode of delivery, Apgar score, perinatal death and maternal complications.
Sixty-two patients were recruited into the study-34 received misoprostol while 28 received oxytocin. The modal gestational age and Bishop score prior at induction were >36 weeks and 5-7 respectively. Hypertension in pregnancy was the commonest indication for induction of labour followed by prolonged pregnancy. The overall induction-delivery interval was 12.2 +/- 5.2 hours; Misoprostol v oxytocin, mean(range): 12.1(7-27) vs 12.3(4-27) hours, p = 0.88). There were no significant differences in the mean Apgar score and perinatal mortality rate in the two study groups. There were two cases of primary postpartum haemorrhage in the oxytocin group but none in the misoprostol group. One case of ruptured uterus was encountered in the misoprostol group. No case of maternal mortality was recorded. Four patients in the misoprostol group had minor side effects mainly nausea and vomiting.
The efficacy of misoprostol in the induction of third trimester labour is comparable to oxytocin. The risk of ruptured uterus associated with misoprostol appears higher than that of oxytocin in the induction of labour. Further studies are needed to verify this observation in our setting.
米索前列醇——一种稳定的前列腺素E1类似物——在引产方面有效且安全。关于在尼日利亚使用米索前列醇引产的信息匮乏。
评估米索前列醇在孕晚期引产中的疗效。
将连续的引产患者随机分为米索前列醇组或缩宫素组。米索前列醇组每6小时阴道内给予50微克,最多4剂。缩宫素组最大剂量为每分钟48国际单位。观察指标包括引产至分娩间隔、分娩方式、阿氏评分、围产期死亡和产妇并发症。
62例患者纳入研究,34例接受米索前列醇,28例接受缩宫素。引产时的孕周中位数和Bishop评分分别>36周和5 - 7分。妊娠期高血压是引产最常见的指征,其次是过期妊娠。总的引产至分娩间隔为12.2±5.2小时;米索前列醇组与缩宫素组,均值(范围):12.1(7 - 27)小时对12.3(4 - 27)小时,p = 0.88)。两组研究对象的平均阿氏评分和围产期死亡率无显著差异。缩宫素组有2例原发性产后出血,米索前列醇组无。米索前列醇组有1例子宫破裂。无产妇死亡记录。米索前列醇组4例患者有轻微副作用,主要为恶心和呕吐。
米索前列醇在孕晚期引产中的疗效与缩宫素相当。在引产中,与米索前列醇相关的子宫破裂风险似乎高于缩宫素。需要进一步研究以在我们的环境中验证这一观察结果。